Hormone therapy for ovarian cancer survivors: systematic review and meta-analysis.
作者信息
Pergialiotis Vasilios, Pitsouni Elina, Prodromidou Anastasia, Frountzas Maximos, Perrea Despina N, Vlachos Georgios D
机构信息
1Laboratory of Experimental Surgery and Surgical Research N.S. Christeas, Athens University Medical School, Athens, Greece 2Division of Gynecologic Oncology, First Department of Obstetrics and Gynecology, Athens University Medical School, Alexandra Hospital, Athens, Greece.
出版信息
Menopause. 2016 Mar;23(3):335-42. doi: 10.1097/GME.0000000000000508.
OBJECTIVE
Hormone therapy (HT) alleviates menopausal symptoms, but there is a lack of consensus regarding its use among premenopausal ovarian cancer survivors.
METHODS
We systematically reviewed the literature and searched the Medline (1966-2014), Scopus (2004-2014), Popline (1974-2014), ClinicalTrials.gov (2008-2014), and Cochrane Central Register of Controlled Trials CENTRAL (1999-2014) databases and the reference lists of electronically retrieved studies. Statistical meta-analysis was performed using RevMan 5.1 software.
RESULTS
Six studies were included in our systematic review, which involved 1,521 women. Among them, 451 women (29.6%) received HT, whereas the remaining 1,070 women (70.4%) did not receive any treatment. We noticed a statistically significant reduction of ovarian cancer-related deaths among women who received HT (odds ratio, 0.47; 95% CI, 0.28-0.80); however, disease recurrence rates did not differ between the two groups (odds ratio, 0.71; 95% CI, 0.45-1.14). Studies included in the present systematic review did not report a significant difference in overall survival and disease-free survival rates among women receiving HT and controls.
CONCLUSIONS
Based on the results of meta-analysis, HT does not influence the odds of ovarian cancer recurrence; however, this conclusion must be confirmed separately because of significant limitations in the methodological quality of the studies included.
Zotero 插件